ABSTRACT
INTRODUCTION
Preterm delivery is associated with several complications and poorer neurophysiological development in early childhood 1 . Randomized clinical trials have shown that antenatal progesterone therapy reduces the rate of preterm delivery among women with a singleton pregnancy who are at high risk due to previous preterm birth 2 -4 or a short cervix in the current pregnancy 5 -7 . Studies including unselected twin-pregnant cohorts have not shown an effect of progesterone treatment 8 , whereas women with twin pregnancy and a short cervix may benefit from progesterone treatment 7, 8 .
Available data are still limited regarding long-term consequences of second-and third-trimester in utero exposure to progesterone 9 . One group studied neurophysiological development in singletons, with follow-up between 2.5 and 5 years, including 270 children born to mothers participating in a randomized placebo-controlled trial of 17α-hydroxyprogesterone caproate in high-risk singleton pregnancies 10 . They found no difference between the two groups with regards to health status, physical examination or neurophysiological development evaluated by the Ages and Stages Questionnaire (ASQ). The first follow-up from the PREDICT (Prevention of Preterm Delivery in Twin Gestations) study that examined twin pregnancies did not find any difference between the progesterone-and placebo-treated groups for neurophysiological development at 6 and 18 months using ASQ. Another study investigated the long-term effects of in-utero progesterone exposure in 759 twins using record linkage as well as two parent-completed validated questionnaires; 324 children were followed-up between 3 and 6 years of age 11 . The authors found no differences between the two treatment groups concerning deaths, congenital anomalies, hospitalization or routine national child health assessments. Recently, the OPPTIMUM trial was published, which was a large double-blinded place-controlled trial investigating the effect of vaginal progesterone in singleton pregnancies at risk of preterm delivery, with follow-up at 2 years of age 12 . Data from 597 women, 587 neonates and 439 2-year-olds in the placebo group and from 600 women, 589 neonates and 430 2-year-olds in the progesterone group were available for analysis. There was no difference between gestational age at delivery, composite neonatal adverse outcomes or any long-term benefit or harm on outcomes in the children at 2 years of age. Intriguingly, however, neonatal ultrasound showed decreased risk of brain injury in the babies born from progesterone-treated mothers.
In the PREDICT study, there was also no effect of progesterone treatment on preterm delivery or short-term outcome of the children. The aim of this study was to perform a long-term neurophysiological follow-up on the surviving Danish children from the PREDICT study, at the age of either 48 or 60 months, and to evaluate their detailed medical histories up to 8 years of age regarding the potentially beneficial or harmful effects of progesterone.
METHODS

Participants
Women and their children from the Danish part of the PREDICT study were included in this follow-up. The PREDICT study is a double-blind, placebo-controlled, randomized clinical trial examining the effect of micronized vaginal progesterone treatment for prevention of preterm delivery in twin pregnancies 9 (clinical trial registration: EudraCT, https://eudract.ema. europa.eu, 2006-000503-41; and ClinicalTrials.gov, www.clinicaltrials.gov, NCT00329914). Women with a diamniotic twin pregnancy were recruited at 18-23 weeks' gestation between 1 June 2006 and 31 October 2008 from 13 hospitals in Denmark and four hospitals in Austria. Exclusion criteria at randomization for the PREDICT study were the following: (1) < 18 years of age; (2) known allergy to progesterone or peanuts; (3) history of hormone-associated thromboembolic disorders; (4) rupture of membranes; (5) treatment for or signs of twin-twin transfusion syndrome (TTTS); (6) fetal reduction; (7) known major structural or chromosomal fetal abnormality; (8) known or suspected malignancy in genitals or breasts; (9) known liver disease; (10) women with higher-order multiple pregnancy; (11) women who did not speak and understand Danish or German, as appropriate. All participants gave written informed consent before enrollment in the PREDICT study. The Danish Data Protection Agency, the Danish and Austrian Medicines Agencies, the Danish Scientific Ethical Committee and the Ethical Committee of the Medical University of Vienna approved the PREDICT study.
Additional exclusion criteria for the current study were the following: (1) part of the Austrian cohort; or (2) either both fetuses or both children had died before the age of 18 months. All participants in the PREDICT study had been asked for permission to contact them again and both parents had been asked for permission to collect follow-up data on their children. If participants and/or spouses had not given consent to further contact and/or follow-up they were also excluded from the current study. The Danish Data Protection Agency approved the follow-up of the twins (2010-41-5175). In Denmark, ethical permission is not required for questionnaires and collection of medical histories.
We thus included children born to Danish women from the PREDICT study who had at least one child alive at the age of 18 months and who, along with her spouse, had given written consent to contact them again and to collect information on their children. Figure 1 shows a flowchart of the study population. A total of 30 Danish women were excluded due to miscarriage or death of both twins (n = 4) or a lack of consent from at least one parent (n = 26). In addition, one woman had emigrated and one woman was lost to follow-up. A total of seven children died before the age of 18 months, including four cases of intrauterine death, two neonatal deaths and one sudden infant death at the age of 6 months. These deaths were all described in the initial report of the PREDICT study 9 . The final population for the follow-up comprised 498 women and 989 children.
The primary outcomes of this study were the possible consequences in twins exposed in utero to either progesterone or placebo, including (1) neurophysiological development at 48 or 60 months of age (n = 437) and (2) admission to hospital and diagnoses up to 8 years of age (n = 989).
Neurophysiological development at 48 or 60 months
We used the ASQ to assess children's neurophysiological development at either 48 or 60 months after the estimated date of delivery. The ASQ is a parent-administered structured questionnaire that includes questions on five domains of child development: gross motor; fine motor; communication; problem solving; and personal/social skills. Each domain has a maximum score of 60 points and the maximum total ASQ score is 300 points. The scores for all areas were summed to give a total score for each child. The questionnaire is validated against the Bayley Scales of infant development 13, 14 . The age-specific questionnaires were sent out according to the estimated date of delivery and not the chronological age of the children, in order to allow for catch-up growth of children delivered preterm. The parents were unblinded to their treatment after completing the 18-months questionnaire, meaning that parents were aware of the treatment they were given when they completed the ASQ at 48 or 60 months. Questionnaires were sent to parents between February 2012 and July 2013. We did not contact the woman again or send new questionnaires to non-responders. The neurophysiological development in the twins had been evaluated previously at 6 months and 18 months after the estimated date of delivery in the PREDICT study 9 .
Medical histories of the twins
We retrieved medical diagnoses from the medical records for each child from April 2014 to November 2014 using the unique civil registration number, with informed consent from both parents. The data retrieved included the total number of hospital admissions and their related diagnoses, as well as all diagnoses made at an outpatient clinic (coded according to the World Health Organization International Classification of Disease, ICD-10). We searched and input all the data manually, then stratified the diagnoses according to the organ system of origin or relevant diagnosis group. Any diagnosis that resulted in multiple admissions of a child was counted only once for each analysis. Out of all the groups of stratified diagnoses, we analyzed the 10 most frequent groups (i.e. comprising > 1% of all diagnoses given; Table S1 ).
Baseline characteristics
Baseline characteristics from the randomized women included maternal age, parity, previous late miscarriage or preterm delivery, body mass index (BMI), marital status, fertility treatment, smoking before and during pregnancy, chorionicity (assigned by standard ultrasonographic criteria based on the presence or absence of the lambda sign and/or two separate placentae 15 ) and gestational age at randomization (based on crown-rump length of the largest fetus at the nuchal translucency scan). These data were collected at the time of randomization in the PREDICT study from background questionnaires and the Astraia database. In the PREDICT study, we also collected information on pregnancy and delivery complications from the women's patient files.
Statistical analysis
All analyses were performed according to the intentionto-treat principle. For the statistical analyses we used Stata, version 12 (StataCorp, College Station, TX, USA). We summarized all baseline characteristics and outcomes using means, medians or frequencies where relevant. Outcomes for women were compared using logistic regression analysis, Student's t-test or Wilcoxon's rank-sum test, where appropriate. For outcomes of the children, the correlation within pairs of twins was accounted for by considering robust estimates of variance based on the method of generalized estimating equations 16 . All analyses were unadjusted. Results are presented as odds ratio (OR) with corresponding 95% CIs or P-values. The placebo-treatment group was used as the reference group and estimates < 1 will therefore indicate favoring of progesterone treatment whereas estimates > 1 will indicate favoring of placebo treatment.
For sensitivity analyses, we performed separate subgroup analyses on diagnoses during admission (i.e. excluding diagnoses made at an outpatient clinic) as well as in dichorionic twins. We also analyzed separately diagnoses made before and after 18 months of age. In these analyses, the same child may be included in both analyses of diagnoses made before and after 18 months of age. Table 1 shows baseline characteristics of the randomized women in the total population. Baseline characteristics of the 32 excluded women were similar to the included women and there were no statistically significant differences between the progesterone and placebo groups.
RESULTS
We analyzed pregnancy and neonatal complications according to treatment group as was done in the original study 9 . These results were similar to previously reported results from the overall trial, i.e. there were no differences in preterm deliveries, adverse maternal outcomes or neonatal complications and mortality according to treatment (data not shown).
There were no new observed deaths of children after the original follow-up at 18 months. Median age at follow-up of diagnoses was 6.6 (range, 5.2-7.9) years in both treatment groups. Median number of admissions was 1.5 (range, 1-77) in the progesterone group and 2 (range, 1-50) in the placebo group. Median duration of admission was 12 (range, 1-547) days in the progesterone group and 13 (range, 1-153) days in the placebo group. We categorized the number of admissions according to the 50 th , 95 th and 98 th centiles, corresponding to > 1, > 5 or > 10 admissions, respectively, and found no significant differences between progesterone-and placebo-exposed children ( Figure 2 ). Likewise, we categorized total days of admission according to the 50 th , 75 th and 95 th centiles, corresponding to > 12, > 24 or > 59 days of admission, Data are given as mean ± SD, n (%) or median (interquartile range). *Excluded for the following: miscarriage (n = 3); both twins died before 18 months after estimated date of delivery (n = 1); at least one parent did not give consent to further follow-up (n = 26); emigrated (n = 1); lost to follow-up (n = 1); some background information was not available for one woman in this group. †Comparison of progesterone and placebo groups. ‡Comparison of women included and those not included. BMI, body mass index; GA, gestational age. Figure 2 Odds ratios for hospital admissions and diagnoses concerning different organ systems in children exposed prenatally to progesterone or placebo in the PREDICT study. For number of admissions, 50 th , 95 th and 98 th centiles were used as cut-offs, and for total days of admission, 50 th , 75 th and 95 th centiles were used as cut-offs.
respectively, and did not find any significant differences between the groups. Figure 2 also shows the ORs for each of the 10 chosen groups of diagnoses for the children exposed prenatally to progesterone compared with placebo. There were no significant differences in the diagnoses made during the follow-up period of up to 8 years of age. One twin, from a placebo-treated mother, was diagnosed with leukemia. Another twin, from a progesterone-treated mother, was diagnosed with terminal kidney failure and tetraplegic cerebral palsy.
Risks of the 10 different diagnoses were not statistically significantly different when subdivided according to age, less than or greater than 18 months, at the time the diagnosis was made (Table 2 ). For diagnoses concerning the lungs, made after 18 months, we examined asthma, pneumonia and other lung-specific diagnoses, which did not show any differences between the two exposure groups (OR, 1.43 (95% CI, 0.94-2.19)).
In the subgroup analysis consisting solely of diagnoses made during admission, i.e. excluding diagnoses at an outpatient clinic, we found an increased risk of a diagnosis related to the heart in progesterone-treated infants (OR, 8.19 (95% CI, 1.02-65.6), P = 0.048). No other differences in admissions for the different diagnoses were identified between treatment groups (Table S2 ).
In the subgroup analyses of dichorionic twins, results were similar, albeit the progesterone-exposed group showed an increased risk of a diagnosis related to the heart (OR, 2.38 (95% CI, 1.07-5.30), P = 0.03, Table S3 ), with diagnoses consisting of septum malformations, other malformations, murmur, rhythm disturbances and aortic aneurysm. However, these results did not remain statistically significant after Bonferroni adjustment.
ASQs were sent to 480 women of the PREDICT study and 220 (45.8%) responded. Table 3 compares the treatment, general maternal characteristics and gestational age at delivery in the ASQ responders and non-responders. The responders had a slightly lower BMI (P = 0.03) and were less likely to be smoking during pregnancy (P = 0.03). Table 4 shows the ASQ scores of the children exposed prenatally to progesterone or placebo in the PREDICT study. Mean age at completion of the ASQ was similar in the two groups and we therefore did not adjust for this variable. We found a significantly higher mean total score (P = 0.03), as well as gross motor skills mean score (P = 0.03), in the progesterone-exposed group compared with the placebo-exposed group. There was no significant difference in the proportion of children with a low ASQ score (defined as < 10 th centile for the population) between the two treatment groups. Subgroup analyses of ASQ scores for dichorionic twins only were similar, though there were more significant differences between the two groups (Table S4 ). The dichorionic twins that were exposed prenatally to progesterone had a higher total mean score (P = 0.01), and higher mean scores in communication (P = 0.04), gross motor skills (P = 0.02) and personal/social skills (P = 0.04). Moreover, dichorionic twins of the progesterone group had a decreased risk for a low total ASQ score (OR, 0.34 (95% CI, 0.14-0.86)) and a low gross motor skills score (OR, 0.43 (95% CI, 0.21-0.90)).
DISCUSSION
The most important finding of this study was that we did not obtain evidence of an overall harmful effect of secondand third-trimester exposure to progesterone in this cohort of 989 twins. On the contrary, the risk of poorer neurophysiological development might be decreased in these infants, which is a novel finding. ASQ scores differed between the treatment groups, with a slightly higher mean total score in the progesterone-exposed group, as well as a higher prevalence of children with a low ASQ score in the placebo-exposed group among dichorionic twins. Our analyses thus suggest that second-and third-trimester in-utero progesterone exposure may result in higher ASQ scores, which could be interpreted as a better neurophysiological outcome in preschool age infants and a decreased risk for a low ASQ score in dichorionic twins. However, one may argue that an overall difference of 7 points between treatment groups is not clinically meaningful and that these findings will need to be replicated before any conclusions can be made. At 6 and 18 months of age in the PREDICT study, there was no difference in ASQ scores between the two exposure groups 9 .
It is important to note that in the subgroup analyses of admissions that excluded diagnoses made at an outpatient clinic and of admissions in dichorionic twins only, we found an increased risk for a diagnosis related to the heart in children exposed prenatally to progesterone (OR, 8.19 (95% CI, 1.02-65.6) and 2.38 (95% CI, 1.07-5.30), respectively). Embryonic development of the heart is completed in the first trimester 17 , and the mothers in our study did not start progesterone treatment until 20-24 weeks of gestation, and thus it seems unlikely that progesterone was the cause of these diagnoses. Also, results did not remain statistically significant after Bonferroni adjustment. However, such an association cannot be ruled out completely. Arrhythmia and suspected heart disease were among the registered diagnoses related to the heart in our study. Previous studies have indicated that progesterone may influence cardiac repolarization, but progesterone has mainly been suggested to have protective effects, for example against long QT-associated arrhythmias in adults 18 . Progesterone is a sex steroid produced naturally by the corpus luteum and, after 10 th week of gestation, by the placenta, and it is essential for maintenance of the pregnancy. It has a direct effect on the myometrium and blocks the effect of prostaglandin F2a and α-adrenergic stimulation 3 . Progesterone also plays a role in neurogenesis, as it is a precursor for allopregnanolone, known to have a protective effect on the developing brain 19 . Animal studies have shown that progesterone provides precursors for the synthesis of the neurosteroids 20 , which contribute largely to the synthesis of allopregnanolone in the developing fetal brain. This results in a large concentration of the neuroactive steroid in the fetal brain during pregnancy compared with after birth. It has been suggested that allopregnanolone is the most important neuroprotective steroid 20 . In animals, neuroactive steroids have a major influence on central nervous system activity and are important for growth and neuronal and glial cell survival 21 . Animal studies suggest that suppression of allopregnanolone synthesis in the fetus increases cell death in the brain and delays myelination of the white-matter tracts 22 -24 . Whether these findings can be applied directly to the developing human brain is still not clear, but one could hypothesize that this action of progesterone could influence the developing brain positively. The recently published OPPTIMUM trial found a decreased risk of brain injury on neonatal ultrasound examinations 12 . Our present observations are thus supported by both basic and clinical science, which provides biological plausibility for intravaginal progesterone to alter neurophysiological end-points. This long-term effect of progesterone could potentially be explored by the use of a prophylactic treatment strategy in fetuses at high risk of decreased allopregnanolone production in the brain, such as those with lower estimated fetal weight or intrauterine growth restriction. Importantly, the synthetic compound 17α-hydroxyprogesterone caproate may not have the same effect. On the contrary, a Data are given as mean ± SD, median (interquartile range) or n (%). BMI, body mass index; GA, gestational age. recent animal study indicates that in-utero exposure to 17α-hydroxyprogesterone caproate may be associated with long-term adverse effects 25 . Further studies are needed to validate the observations and studies are needed to better define subpopulations that may respond to the intervention. Progesterone treatment for this indication is therefore not advisable based on the present study and should await additional phase-III studies.
Our results of no harmful effects of progesterone treatment in pregnancy are supported by two other studies that performed follow-up at 4-5 years of age after in-utero progesterone exposure. The randomized STOPPIT follow-up study included 759 children in an analysis of overall health and 162 twin pairs in an analysis of their neurophysiological development 11 . The women included in that study also received vaginal progesterone. The study evaluated overall health by routine health check-ups, mortality and primary diagnoses at time of admission, as well as total days of admission. It used an alternative parent-administered questionnaire to that used in our study, though still validated. All of the results showed no differences between the two groups. The other randomized trial administered intramuscular progesterone in singleton pregnancies. Follow-up was performed using ASQ (n = 275), a health survey questionnaire (n = 274) and a physical examination (n = 270). The study did not find any differences between the two groups 10 . Strengths of our study include the thorough health follow-up, which we were able to perform due to the unique civil registration system available in Denmark. Moreover, the randomization and the large number of children available for follow-up, regarding both their overall health (n = 989) and their neurophysiological development (n = 437), makes it the largest long-term follow-up study to date concerning secondand third-trimester progesterone exposure, with up to 8 years of follow-up. Another strength of this study is the fact that there was no difference between gestational age at delivery in the randomized groups, i.e. we measured the effect of progesterone and not the gestational age at delivery. One weakness of our study is that the parents were unblinded after completing the 18-months questionnaire and therefore were not blinded to treatment when they completed the ASQ at 48 or 60 months. This could have resulted in an exaggeration or an understatement of their children's abilities and performances in the progesterone-treated group, obscuring their opinion of their child's neurophysiological development. Furthermore, we had a rather large group of non-responders in the present follow-up, but when comparing the baseline characteristics of the mothers in the two groups, there were no significant differences, besides the trends that more of the non-responders were smokers and had higher BMI. There was no difference in response rate between the two treatment groups. Our current results of no harmful effects of prenatal progesterone exposure are in accordance with our results from the initial reporting at 6 and 18 months after the estimated date of delivery. However, one must also acknowledge the fact that the statistical power of our current follow-up study may have been inadequate for some of the examined outcomes, for which a larger sample size may have yielded significant results.
In conclusion, second-and third-trimester exposure of a fetus to progesterone does not seem to have long-term harmful effects in childhood. Future studies should, however, focus on cardiac disease in the child, as we cannot reject an association with progesterone exposure. Future randomized blinded trials are needed in order to conclude on long-term effects of progesterone.
SUPPORTING INFORMATION ON THE INTERNET
The following supporting information may be found in the online version of this article: Table S1 Frequencies of diagnoses given in the 989 children from the PREDICT study according to organ system or other diagnosis group. A total of 2621 admissions and outpatient diagnoses were recorded Table S2 Diagnoses given during admissions (i.e. excluding diagnoses given at outpatient clinic visits) according to treatment group: progesterone (n = 492 children) or placebo (n = 497 children) Table S3 Admissions and diagnoses (given during admissions as well as outpatient clinic visits) in dichorionic twins according to treatment group: progesterone (n = 444 children) or placebo (n = 425 children) 
